Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, Dwek RA, Platt FM.

Ann Neurol. 2004 Nov;56(5):642-9. Erratum in: Ann Neurol. 2005 Jan;57(1):156.

PMID:
15505823
2.

Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.

Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM.

Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388-93.

3.

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.

Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM.

Brain. 2003 Apr;126(Pt 4):974-87.

4.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, Platt FM.

Neurobiol Dis. 2004 Aug;16(3):506-15.

PMID:
15262262
5.

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.

Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH.

J Biol Chem. 2003 Aug 8;278(32):29496-501.

PMID:
12756243
6.

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.

Jeyakumar M, Norflus F, Tifft CJ, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA, Platt FM.

Blood. 2001 Jan 1;97(1):327-9.

7.

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.

Baek RC, Kasperzyk JL, Platt FM, Seyfried TN.

Neurochem Int. 2008 May;52(6):1125-33. doi: 10.1016/j.neuint.2007.12.001.

PMID:
18207611
8.

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.

Denny CA, Heinecke KA, Kim YP, Baek RC, Loh KS, Butters TD, Bronson RT, Platt FM, Seyfried TN.

J Neurochem. 2010 Jun;113(6):1525-35. doi: 10.1111/j.1471-4159.2010.06733.x.

9.

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE.

Brain. 2005 Jun;128(Pt 6):1442-53.

10.

Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice.

Denny CA, Kasperzyk JL, Gorham KN, Bronson RT, Seyfried TN.

J Neurosci Res. 2006 May 1;83(6):1028-38.

PMID:
16521125
11.

Antioxidant and antiinflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia.

Lim CS, Jin DQ, Mok H, Oh SJ, Lee JU, Hwang JK, Ha I, Han JS.

J Neurosci Res. 2005 Dec 15;82(6):831-8.

PMID:
16273545
12.

Anti-inflammatory effects of aronia extract on rat endotoxin-induced uveitis.

Ohgami K, Ilieva I, Shiratori K, Koyama Y, Jin XH, Yoshida K, Kase S, Kitaichi N, Suzuki Y, Tanaka T, Ohno S.

Invest Ophthalmol Vis Sci. 2005 Jan;46(1):275-81.

PMID:
15623784
13.

Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.

Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD.

Science. 1997 Apr 18;276(5311):428-31.

14.

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.

Ashe KM, Bangari D, Li L, Cabrera-Salazar MA, Bercury SD, Nietupski JB, Cooper CG, Aerts JM, Lee ER, Copeland DP, Cheng SH, Scheule RK, Marshall J.

PLoS One. 2011;6(6):e21758. doi: 10.1371/journal.pone.0021758.

15.

Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages.

Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ.

J Neuroimmunol. 2005 Aug;165(1-2):139-49.

PMID:
15975667
16.

Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.

Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S355-61. doi: 10.1007/s10545-010-9186-3.

PMID:
20821051
17.
18.

Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.

Arthur JR, Lee JP, Snyder EY, Seyfried TN.

Neurochem Res. 2012 Jun;37(6):1335-43. doi: 10.1007/s11064-012-0718-0.

PMID:
22367451
19.

Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores.

Martin F, Penet MF, Malergue F, Lepidi H, Dessein A, Galland F, de Reggi M, Naquet P, Gharib B.

J Clin Invest. 2004 Feb;113(4):591-7.

20.

Synthesis of new diselenide compounds as anti-inflammatory agents.

Shen L, Shin KM, Lee KT, Jeong JH.

Arch Pharm Res. 2004 Aug;27(8):816-9.

PMID:
15460440
Items per page

Supplemental Content

Support Center